 Matthew Reichlen
Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 7 | 2026 | 318 | 1.680 |
Why?
| | Tuberculosis | 5 | 2026 | 283 | 1.150 |
Why?
| | Antitubercular Agents | 6 | 2026 | 208 | 0.970 |
Why?
| | Methanosarcina | 3 | 2012 | 3 | 0.750 |
Why?
| | Archaeal Proteins | 3 | 2012 | 50 | 0.740 |
Why?
| | Gene Expression Regulation, Archaeal | 3 | 2012 | 9 | 0.710 |
Why?
| | Anti-Infective Agents | 1 | 2023 | 232 | 0.620 |
Why?
| | Bacteria, Anaerobic | 1 | 2017 | 25 | 0.520 |
Why?
| | Regulon | 1 | 2017 | 34 | 0.520 |
Why?
| | Bacterial Proteins | 3 | 2026 | 962 | 0.510 |
Why?
| | Cell Death | 1 | 2017 | 382 | 0.470 |
Why?
| | TATA-Box Binding Protein | 1 | 2010 | 20 | 0.310 |
Why?
| | Microbial Sensitivity Tests | 3 | 2026 | 363 | 0.250 |
Why?
| | Methane | 3 | 2012 | 45 | 0.220 |
Why?
| | Transcription Factors | 1 | 2012 | 1731 | 0.210 |
Why?
| | Mycobacterium | 1 | 2023 | 101 | 0.180 |
Why?
| | Enzyme Inhibitors | 1 | 2026 | 820 | 0.180 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 110 | 0.180 |
Why?
| | Benchmarking | 1 | 2023 | 188 | 0.170 |
Why?
| | RNA, Ribosomal | 1 | 2021 | 168 | 0.160 |
Why?
| | RNA Precursors | 1 | 2021 | 154 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 339 | 0.140 |
Why?
| | Bacillus | 1 | 2017 | 17 | 0.130 |
Why?
| | Cell Respiration | 1 | 2017 | 105 | 0.130 |
Why?
| | Electron Transport | 1 | 2017 | 110 | 0.130 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2017 | 531 | 0.120 |
Why?
| | Adenosine Triphosphate | 1 | 2017 | 499 | 0.110 |
Why?
| | Clofazimine | 1 | 2014 | 15 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2026 | 1261 | 0.100 |
Why?
| | Granuloma | 1 | 2014 | 97 | 0.100 |
Why?
| | Homeostasis | 1 | 2017 | 639 | 0.100 |
Why?
| | Biosynthetic Pathways | 1 | 2012 | 24 | 0.090 |
Why?
| | Oxygen | 1 | 2017 | 978 | 0.090 |
Why?
| | RNA, Archaeal | 1 | 2011 | 12 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 2023 | 1454 | 0.080 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2011 | 62 | 0.080 |
Why?
| | Archaea | 1 | 2011 | 61 | 0.080 |
Why?
| | Genome, Archaeal | 1 | 2010 | 12 | 0.080 |
Why?
| | Methanosarcinaceae | 1 | 2009 | 2 | 0.070 |
Why?
| | Coal | 1 | 2009 | 18 | 0.070 |
Why?
| | Seawater | 1 | 2009 | 33 | 0.070 |
Why?
| | Geologic Sediments | 1 | 2009 | 46 | 0.070 |
Why?
| | Gene Deletion | 1 | 2010 | 391 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1244 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1922 | 0.060 |
Why?
| | Carbon Monoxide | 1 | 2006 | 82 | 0.060 |
Why?
| | Pyrazinamide | 1 | 2026 | 16 | 0.060 |
Why?
| | Protein Binding | 1 | 2012 | 2235 | 0.060 |
Why?
| | Isoniazid | 1 | 2026 | 70 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2023 | 4552 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2006 | 227 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2026 | 167 | 0.050 |
Why?
| | Mice | 4 | 2026 | 18303 | 0.050 |
Why?
| | High-Throughput Screening Assays | 1 | 2026 | 175 | 0.050 |
Why?
| | Mycobacterium smegmatis | 1 | 2023 | 14 | 0.050 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2023 | 337 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1043 | 0.040 |
Why?
| | RNA, Bacterial | 1 | 2021 | 182 | 0.040 |
Why?
| | Proteomics | 1 | 2006 | 1185 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2023 | 560 | 0.040 |
Why?
| | Animals | 4 | 2026 | 37952 | 0.040 |
Why?
| | Humans | 4 | 2026 | 145140 | 0.030 |
Why?
| | Transcriptome | 1 | 2023 | 1029 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1763 | 0.030 |
Why?
| | Bacterial Load | 1 | 2014 | 67 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2014 | 254 | 0.030 |
Why?
| | Female | 4 | 2026 | 78636 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 2009 | 2881 | 0.020 |
Why?
| | Necrosis | 1 | 2014 | 243 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 5972 | 0.020 |
Why?
| | Transcription Factors, General | 1 | 2011 | 5 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2014 | 784 | 0.020 |
Why?
| | Eukaryota | 1 | 2011 | 56 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2011 | 485 | 0.020 |
Why?
| | Louisiana | 1 | 2009 | 31 | 0.020 |
Why?
| | Base Composition | 1 | 2009 | 82 | 0.020 |
Why?
| | DNA, Archaeal | 1 | 2009 | 18 | 0.020 |
Why?
| | Anaerobiosis | 1 | 2009 | 65 | 0.020 |
Why?
| | Methanol | 1 | 2009 | 44 | 0.020 |
Why?
| | Culture Media | 1 | 2009 | 161 | 0.020 |
Why?
| | Species Specificity | 1 | 2009 | 545 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3114 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2009 | 507 | 0.020 |
Why?
| | Operon | 1 | 2006 | 67 | 0.020 |
Why?
| | Acetates | 1 | 2006 | 78 | 0.020 |
Why?
| | Oxidoreductases | 1 | 2006 | 91 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 776 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2021 | 11741 | 0.010 |
Why?
| | Phylogeny | 1 | 2009 | 917 | 0.010 |
Why?
| | Bacteria | 1 | 2011 | 765 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2168 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1066 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2127 | 0.010 |
Why?
| | Lung | 1 | 2014 | 4101 | 0.010 |
Why?
|
|
Reichlen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|